Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Gabriella McCarty

NP-C

Gabriella McCarty is a gastroenterology/hepatology nurse practitioner. She obtained her masters and nurse practitioner degree at Case Western Reserve University in 2004. She has been practicing in this field for 26 years. She serves as faculty for Gastroenterology/ Hepatology Advanced Practice Providers (GHAPP) and is an American College of Gastroenterology (ACG) committee member, serving on the education subcommittee. She will be completing her doctorate of nursing in May 2025. She loves all aspects of GI / Hepatology, education and nursing.

play

Alison Moe

PA-C

Alison S. Moe, MS, PA-C, is a board-certified physician assistant specializing in gastroenterology at United Digestive's Braselton office in Hoschton, Georgia. She earned her Master of Science in Medical Education from Seton Hall University and a Bachelor of Arts in Physical Anthropology from the State University of New York at Stony Brook. Alison is fluent in Spanish and has a special interest in treating irritable bowel syndrome and liver disease. With almost two decades of experience as a Physician Assistant, Alison has developed a strong foundation in both clinical practice and research, particularly in the fields of gastroenterology and hepatology. Alison's dedication to patient care includes extensive clinical hours, allowing her to cultivate deep relationships with patients as well as national experts caring for individuals, especially those suffering from inflammatory bowel disease (IBD) and advanced liver disease. Alison's commitment to advancing the understanding and treatment of these conditions drives my clinical practice and ongoing research efforts, aiming to provide the highest standard of care for my patients.

play

Christie Morrison

AGACNP-BC

Christie Morrison is a Board Certified Adult Advanced Practice Nurse and Lead APP at Oshi Health, a digital digestive health practice and IBD APP at Texas Digestive Disease Consultants in San Antonio, Texas. She strives to improve the lives of patients with chronic gastrointestinal conditions through a multidisciplinary approach. She has worked in various roles as a GI advanced practice provider, including inpatient, outpatient clinic, and telehealth since 2015. Mrs. Morrison is currently an active member of the American College of Gastroenterology where she is serving on the Editorial Board. She is also a member of several GI societies, including TSGE, AGA, ASGE, and GHAPP. Christie was recently honored with the ACG APP Clinical Excellence Award for community practice. She collaborates with industry partners and GI colleagues to enhance education and engagement for APPs working in Gastroenterology. She strives to improve the quality of life and better patient outcomes in all chronic GI conditions and believes that providing resources to her peers through education can help her achieve this goal.

MASLD/MASH Learning Center

Latest News & Blogs

UPLC-MS/MS Metabolomics Reveals Babao Dan's Mechanisms in MASH Treatment with Integrating Network Pharmacology and Molecular Docking

August 2025

Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive disease that easily develops into cirrhosis and hepatocellular carcinoma, but its pathogenesis is not clear, and most therapeutic drugs have obvious limitations. However, Babao Dan (BBD) has a good therapeutic effect on liver disease, but its treatment mechanism is still to be studied. Therefore, we further investigated the mechanism of BBD in treating MASH. Methods: We predicted BBD-related targets through...

Read More arrow

Therapeutic Potential of Probiotics in Metabolic Dysfunction-Associated Steatohepatitis: A Comprehensive Review

August 2025

Metabolic dysfunction-associated steatohepatitis (MASH) constitutes a significant and progressive liver disease, characterized by a complex pathogenesis that involves dysbiosis of the gut microbiota. While the multifaceted nature of MASH is widely recognized, its underlying mechanisms remain the subject of active investigation. Contemporary research highlights the critical role of the gut-liver axis, suggesting that disturbances in the gut microbiome may contribute to the progression of the...

Read More arrow

Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly increases the risk of steatohepatitis and cirrhosis and multiple extrahepatic complications, in particular, cardiometabolic disease, including type 2 diabetes, atherosclerotic cardiovascular disease (CVD), and heart failure, with a significant negative impact on health-related quality of life, becoming a substantial economic burden. Moreover, cardiovascular events represent the leading cause of death in MASLD...

Read More arrow

Liver Sinusoidal Endothelial Cells and Their Regulation of Immunology, Collagenization, and Bioreactivity in Fatty Liver: A Narrative Review

August 2025

Liver sinusoidal endothelial cells (LSECs) are essential for preserving liver homeostasis. Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a category of hepatic disorders characterized by excessive fat accumulation in the liver, known as steatosis. Over time, accumulated hepatic fat can induce inflammation of the liver (hepatitis). MASLD is among the most prevalent types of chronic liver disease. Obesity and Type 2 diabetes mellitus (T2DM) are frequent etiological...

Read More arrow

Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are among the most prevalent causes of chronic liver disease worldwide, closely linked to the global rise in overweight and obesity, type 2 diabetes, and metabolic syndrome. Until recently, treatment options were limited to lifestyle interventions, with no approved pharmacologic therapies. Resmetirom, a liver-directed, selective thyroid hormone...

Read More arrow

The Role of Aldosterone and the Mineralocorticoid Receptor in Metabolic Dysfunction-Associated Steatotic Liver Disease

August 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is one of the fastest-growing hepatic disorders worldwide. During its natural course, MASLD tends to progress from isolated steatosis of the liver to Metabolic Dysfunction-Associated Alcoholic Steatohepatitis (MASH), advanced fibrosis, and finally cirrhosis, with the risk of developing hepatocellular carcinoma (HCC). Although frequently related to overweight or obesity and other components of the metabolic syndrome (MS), MASLD can...

Read More arrow

Targeting Lipophagy in Liver Diseases: Impact on Oxidative Stress and Steatohepatitis

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a range of liver conditions, from simple hepatic steatosis to its more severe inflammatory form known as metabolic dysfunction-associated steatohepatitis (MASH). Despite its growing clinical significance and association with cirrhosis and cancer, there are currently few pharmacological treatments available for MASLD, highlighting the urgent need for new therapeutic strategies. This narrative review aims to elucidate the...

Read More arrow

Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States

August 2025

CONCLUSION: The use of cT1 to assign and monitor resmetirom treatment improves treatment allocation and reduces health system cost vs VCTE and liver biopsy.

Read More arrow

Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials

August 2025

CONCLUSIONS: The MD and aerobic exercise, whether alone or combined with resistance training, support weight loss and improve liver health in patients with MASLD/MASH. Standardized methods for measuring and reporting outcomes are essential to build robust evidence on the impact of lifestyle changes on clinical outcomes. TRIAL REGISTRATION: PROSPERO registration code. CRD42024577846.

Read More arrow

Loss of hepatic carboxylesterase 3 (CES3) prevents the development of MASLD in mice

August 2025

Carboxylesterases (CES) are essential for metabolizing compounds with ester, thioester, and amide bonds. While the roles of CES1 and CES2 in lipid metabolism have been well established, little is known about the role of CES3 in lipid metabolism or metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we report the localization and nutritional regulation of CES3 and its role in MASLD development in mice. CES3 is expressed exclusively in the liver and localizes to the endoplasmic...

Read More arrow

Adipocyte-specific deletion of gp130 prevents ketogenic diet-induced hepatic steatosis

August 2025

CONCLUSIONS: Our studies demonstrate the importance of adipose tissue-liver crosstalk in mediating MASLD progression and identify adipocyte IL-6-gp130 as a potential therapeutic target.

Read More arrow

Non-Invasive Tests: Establishing efficacy for metabolic dysfunction associated steatohepatitis beyond the biopsy-current perspectives from the division of hepatology and nutrition, US Food and Drug Administration

August 2025

To support drug development for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, multiple stakeholders including patients, clinicians, and investigators have communicated a desire to move away from liver histology. FDA accelerated approval is based on a surrogate endpoint (such as liver histology) that has less definitive evidence tying it to the clinical endpoint (such as death or liver transplant) but nonetheless is considered reasonably likely to predict clinical benefit...

Read More arrow

CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis

August 2025

CONCLUSIONS: Our findings reveal a novel role for CD44 in regulating the dynamics of group 1 ILCs, which in turn affects steatohepatitis and MASLD development.

Read More arrow

Application of machine learning and deep learning in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis

August 2025

CONCLUSIONS: Both ML and DL models demonstrated strong diagnostic performance for MASH and liver fibrosis, with DL achieving marginally higher AUROCs. AI-driven approaches show promise in MASLD management.

Read More arrow

New Names, New Drugs, Better Outcomes in Steatotic Liver Disease

August 2025

Steatotic liver disease (SLD) is a growing cause of chronic liver disease, with potential progression to cirrhosis, hepatocellular carcinoma (HCC), and liver failure. Previously known as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new terminology, including metabolic-dysfunction associated steatotic liver disease (MASLD) and metabolic-dysfunction associated steatohepatitis (MASH), was introduced to improve diagnostic clarity and reduce stigmatization....

Read More arrow

Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of metabolic syndrome. Hepatic lipotoxicity and inflammation are two key factors driving progression of steatosis to metabolic dysfunction-associated steatohepatitis (MASH). The presence of MASH increases the risk of cardiovascular events, cirrhosis, hepatocellular carcinoma (HCC) and non-liver malignancies. Although MASLD and lipid species have been extensively examined in persons with type 2 diabetes,...

Read More arrow

Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

August 2025

BACKGROUND: ION224, a liver-directed antisense inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2), suppresses de novo lipogenesis, an important metabolic pathway associated with lipotoxicity and the underlying inflammation, hepatocellular injury, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to prospectively assess the safety and efficacy of ION224 in patients with MASH and fibrosis.

Read More arrow

Fibroblast growth factor receptor inhibitors ameliorate metabolic dysfunction-associated steatohepatitis by modulating the glycine-glutathione-gut microbiota axis

August 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease characterized by hepatic steatosis, inflammation, and fibrosis. Dysregulation of fibroblast growth factor receptor (FGFR) signaling is closely associated with various liver diseases, but its role in hepatic metabolism remains unclear. In this study, we developed a small-molecule FGFR inhibitor, CP0813, and evaluated its therapeutic potential in three diet-induced MASH mouse models. Using multi-omics analyses...

Read More arrow

Delineating unique MASH-endothelial cells in metabolic dysfunction-associated steatotic liver disease using single-cell lensing

August 2025

CONCLUSIONS: In summary, our study delineates the unique features of MASH-EC, enhancing our understanding of endothelial cell dysfunction in MASLD and laying the groundwork for future investigations into targeted therapeutic strategies.

Read More arrow

Peroxynitrite is key to Cylindrospermopsin-mediated MASLD to MASH progression via triggering TXNIP binding to NLRP3 and subsequent inflammasome activation

August 2025

Harmful algal bloom (HAB) toxins are shown to be associated with Metabolic dysfunction-associated steatohepatitis (MASH) progression. Several studies link the HAB toxin microcystin to hepatic inflammasome activation, but the role of cylindrospermopsin (CYN) in Metabolic dysfunction-associated steatotic liver disease (MASLD) pathology remains unknown. Using a mouse model of MASLD, we show that CYN exposure served as a second hit for MASLD to MASH progression, as shown by histopathology and NAS...

Read More arrow